FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165367788> ?p ?o ?g. }

• W2165367788 endingPage "33" @default.
• W2165367788 startingPage "24" @default.
• W2165367788 abstract "Background In phase I clinical trials, the “3+3” algorithmic design has been unparalleled in its popularity. The statistical properties of the “3+3” design have been studied in the literature either in comparison with other methods or by deriving exact formulae of statistical quantities. However, there is still much to be known about its capabilities of describing and accounting for uncertainties in the observed data. Purpose The objective of this study is to provide a probabilistic support for analyzing the heuristic performance of the “3+3” design. The operating characteristics of the algorithm are computed under different hypotheses, levels of evidence, and true (or best guessed) toxicity rates. The dose-finding rules are further compared with those generated by the modified toxicity probability interval design and generalized for implementation in all “A+B” designs. Methods Our likelihood method is based on the evidential paradigm. Two hypotheses are chosen to correspond to two hypothesized dose-limiting toxicity rates, for example, [Formula: see text]—unsafe versus [Formula: see text]—acceptable. Given observed toxicities per dose, the likelihood-ratio is calculated and compared to a certain k threshold (level of evidence). Under various true toxicities, the probabilities of weak evidence, favoring [Formula: see text] and [Formula: see text], were computed under four sets of hypotheses and several k thresholds. Results For scenarios where the midpoint of the two hypothesized dose-limiting toxicity rates is around 0.30, and for a threshold of k = 2, the “3+3” design has a reduced probability (≈0.50) of identifying unsafe doses, but high chances of identifying acceptable doses. For more extreme scenarios targeting a relatively high or relatively low dose-limiting toxicity rate, the “3+3” design has no probabilistic support, and therefore, it should not be used. In our comparisons, the likelihood method is in agreement with the modified toxicity probability interval design for the majority of the hypothesized scenarios. Even so, based on the evidential paradigm, a “3+3” design is often incapable of providing sufficient levels of evidence of acceptability for doses under reasonable scenarios. Limitations Given the small sample size per dose, the levels of evidence are limited in their ability to provide strong evidence favoring either of the hypotheses. Conclusion In many situations, the “3+3” design does not treat enough patients per dose to have confidence in correct dose selection and the safety of the selected/unselected doses. This likelihood method allows consistent inferences to be made at each dose level, and evidence to be quantified regardless of cohort size. The approach can be used in phase I studies for identifying acceptably safe doses, but also for defining stopping rules in other types of dose-finding designs." @default.
• W2165367788 created "2016-06-24" @default.
• W2165367788 creator A5029296725 @default.
• W2165367788 creator A5033233067 @default.
• W2165367788 creator A5080170238 @default.
• W2165367788 date "2014-10-27" @default.
• W2165367788 modified "2023-10-10" @default.
• W2165367788 title "A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs" @default.
• W2165367788 cites W1965231777 @default.
• W2165367788 cites W1972747033 @default.
• W2165367788 cites W2004133377 @default.
• W2165367788 cites W2015506353 @default.
• W2165367788 cites W2030672763 @default.
• W2165367788 cites W2044316798 @default.
• W2165367788 cites W2045985885 @default.
• W2165367788 cites W2054383376 @default.
• W2165367788 cites W2076108528 @default.
• W2165367788 cites W2078274740 @default.
• W2165367788 cites W2103105040 @default.
• W2165367788 cites W2110340629 @default.
• W2165367788 cites W2143893263 @default.
• W2165367788 cites W2149344761 @default.
• W2165367788 cites W2158740848 @default.
• W2165367788 cites W2167228337 @default.
• W2165367788 cites W2587865575 @default.
• W2165367788 cites W4230704549 @default.
• W2165367788 doi "https://doi.org/10.1177/1740774514555585" @default.
• W2165367788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4344878" @default.
• W2165367788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25349178" @default.
• W2165367788 hasPublicationYear "2014" @default.
• W2165367788 type Work @default.
• W2165367788 sameAs 2165367788 @default.
• W2165367788 citedByCount "6" @default.
• W2165367788 countsByYear W21653677882015 @default.
• W2165367788 countsByYear W21653677882016 @default.
• W2165367788 countsByYear W21653677882018 @default.
• W2165367788 countsByYear W21653677882022 @default.
• W2165367788 crossrefType "journal-article" @default.
• W2165367788 hasAuthorship W2165367788A5029296725 @default.
• W2165367788 hasAuthorship W2165367788A5033233067 @default.
• W2165367788 hasAuthorship W2165367788A5080170238 @default.
• W2165367788 hasBestOaLocation W21653677882 @default.
• W2165367788 hasConcept C105795698 @default.
• W2165367788 hasConcept C11413529 @default.
• W2165367788 hasConcept C114614502 @default.
• W2165367788 hasConcept C126255220 @default.
• W2165367788 hasConcept C127413603 @default.
• W2165367788 hasConcept C173801870 @default.
• W2165367788 hasConcept C188198153 @default.
• W2165367788 hasConcept C2524010 @default.
• W2165367788 hasConcept C2778067643 @default.
• W2165367788 hasConcept C33923547 @default.
• W2165367788 hasConcept C34130140 @default.
• W2165367788 hasConcept C41008148 @default.
• W2165367788 hasConcept C44249647 @default.
• W2165367788 hasConcept C49937458 @default.
• W2165367788 hasConcept C78519656 @default.
• W2165367788 hasConceptScore W2165367788C105795698 @default.
• W2165367788 hasConceptScore W2165367788C11413529 @default.
• W2165367788 hasConceptScore W2165367788C114614502 @default.
• W2165367788 hasConceptScore W2165367788C126255220 @default.
• W2165367788 hasConceptScore W2165367788C127413603 @default.
• W2165367788 hasConceptScore W2165367788C173801870 @default.
• W2165367788 hasConceptScore W2165367788C188198153 @default.
• W2165367788 hasConceptScore W2165367788C2524010 @default.
• W2165367788 hasConceptScore W2165367788C2778067643 @default.
• W2165367788 hasConceptScore W2165367788C33923547 @default.
• W2165367788 hasConceptScore W2165367788C34130140 @default.
• W2165367788 hasConceptScore W2165367788C41008148 @default.
• W2165367788 hasConceptScore W2165367788C44249647 @default.
• W2165367788 hasConceptScore W2165367788C49937458 @default.
• W2165367788 hasConceptScore W2165367788C78519656 @default.
• W2165367788 hasIssue "1" @default.
• W2165367788 hasLocation W21653677881 @default.
• W2165367788 hasLocation W21653677882 @default.
• W2165367788 hasLocation W21653677883 @default.
• W2165367788 hasLocation W21653677884 @default.
• W2165367788 hasOpenAccess W2165367788 @default.
• W2165367788 hasPrimaryLocation W21653677881 @default.
• W2165367788 hasRelatedWork W2037106203 @default.
• W2165367788 hasRelatedWork W2079857752 @default.
• W2165367788 hasRelatedWork W2129061411 @default.
• W2165367788 hasRelatedWork W2272916823 @default.
• W2165367788 hasRelatedWork W2353608563 @default.
• W2165367788 hasRelatedWork W2361785418 @default.
• W2165367788 hasRelatedWork W2368520543 @default.
• W2165367788 hasRelatedWork W3091779247 @default.
• W2165367788 hasRelatedWork W37565017 @default.
• W2165367788 hasRelatedWork W647236485 @default.
• W2165367788 hasVolume "12" @default.
• W2165367788 isParatext "false" @default.
• W2165367788 isRetracted "false" @default.
• W2165367788 magId "2165367788" @default.
• W2165367788 workType "article" @default.